Mercilon Tafla 150 míkróg/20 míkróg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

mercilon tafla 150 míkróg/20 míkróg

n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg

Vidisic Augnhlaup 2 mg/g アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

vidisic augnhlaup 2 mg/g

gerhard mann dr., chem.-pharm. fabrik gmbh - carbomerum inn - augnhlaup - 2 mg/g

Hyprosan (Hypromellose) Augndropar, lausn 3,2 mg/ml アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

hyprosan (hypromellose) augndropar, lausn 3,2 mg/ml

santen oy - hypromellosum inn - augndropar, lausn - 3,2 mg/ml

Oftagel Augnhlaup 2,5 mg/g アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

oftagel augnhlaup 2,5 mg/g

santen oy* - carbomer - augnhlaup - 2,5 mg/g

Oftagel Augnhlaup í stakskammtaíláti 2,5 mg/g アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

oftagel augnhlaup í stakskammtaíláti 2,5 mg/g

santen oy* - carbomer - augnhlaup í stakskammtaíláti - 2,5 mg/g

Oculac Augndropar, lausn 5 % アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

oculac augndropar, lausn 5 %

alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %

Oculac án rotvarnar Augndropar, lausn 5 % アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

oculac án rotvarnar augndropar, lausn 5 %

alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %

Bleomycin Baxter Stungulyfs-/innrennslisstofn, lausn 15.000 a.e. アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

bleomycin baxter stungulyfs-/innrennslisstofn, lausn 15.000 a.e.

baxter medical ab* - bleomycinum súlfat - stungulyfs-/innrennslisstofn, lausn - 15.000 a.e.

Ikervis 欧州連合 - アイスランド語 - EMA (European Medicines Agency)

ikervis

santen oy - ciclosporin - kviðsjúkdómar - augnlækningar - meðferð við alvarlegum glærubólgu hjá fullorðnum sjúklingum með þurr auganu, sem hefur ekki batnað þrátt fyrir meðferð með tárubólgu.

Blenrep 欧州連合 - アイスランド語 - EMA (European Medicines Agency)

blenrep

glaxosmithkline (ireland) limited - belantamab mafodotin - mergæxli - Æxlishemjandi lyf - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.